Reboxetine Therapy for Narcolepsy With Cataplexy Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for narcolepsy, particularly narcolepsy with cataplexy, are limited by variability in efficacy, tolerability issues, and the need for Drug Enforcement Administration (DEA) scheduling, making them inadequate for this under-diagnosed orphan condition.
Innovation Solution
Administering selective norepinephrine inhibitors such as atomoxetine, edivoxetine, or reboxetine to treat narcolepsy with cataplexy, which includes dosages of 8-10 mg daily for at least two weeks, resulting in significant reductions in cataplexy attacks, improved concentration, and enhanced sleep quality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current approved treatments are used for narcolepsy, then some therapeutic effect is achieved, but efficacy varies significantly from patient to patient and tolerability issues arise
Solution Approach 1:
The patent changes the pharmacological parameter by switching from stimulant-based treatments to selective norepinephrine reuptake inhibitors, fundamentally altering the mechanism of action to achieve more consistent efficacy and better tolerability across patients
2Ease of operation
If current approved treatments are used for narcolepsy, then some symptom relief is provided, but the need for DEA scheduling limits treatment options
Solution Approach 1:
The patent extracts the therapeutic effect from DEA-scheduled stimulants by using non-scheduled selective norepinephrine reuptake inhibitors, removing the regulatory burden while maintaining treatment efficacy
3Reliability
If reboxetine is administered at 8-10 mg daily for at least two weeks, then cataplexy attacks are reduced by at least 30%, but the treatment duration requirement may delay symptom relief
Solution Approach 1:
The patent establishes preliminary dosing guidelines of 8-10 mg daily for at least two weeks to ensure therapeutic norepinephrine levels are achieved and maintained, optimizing the probability of cataplexy attack reduction while managing the time delay through structured treatment protocols
Data Source
AI summary
Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.